ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, N.
Right arrow Articles by Payne, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, N.
Right arrow Articles by Payne, S.
Eur Respir J 1993; 6: 877-885
Copyright © ERS Journals Ltd 1993


Clinical Trial

A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group

NC Barnes, G Marone, GU Di Maria, S Visser, I Utama, and SL Payne

We wanted to compare the efficacy and safety of fluticasone propionate, a new topically active inhaled corticosteroid, to that of high dose beclomethasone dipropionate, in severe adult asthma. Patients currently receiving between 1.5-2.0 mg.day-1 of an inhaled corticosteroid were treated for six weeks in a double-blind, randomized, parallel group study with 1 mg.day-1 fluticasone propionate (n = 82), or 2 mg.day-1 beclomethasone dipropionate (n = 72). Mean morning peak expiratory flow rates (PEFR) increased from 303 to 321 l.min-1 with fluticasone propionate, and from 294 to 319 l.min-1 with beclomethasone dipropionate. There was an increase in evening PEFR, asthma symptoms improved, and rescue beta 2-agonist use decreased for both treatment groups. None of these differences between treatments were statistically significant. However, diurnal variation was significantly reduced with fluticasone propionate, when compared with beclomethasone dipropionate (difference = 7 l.min-1; p = 0.038). Clinic lung function also improved with both treatments and, apart from % predicted PEFR, which showed no difference after beclomethasone dipropionate but increased from 73 to 78% with fluticasone propionate, there were no differences between treatments. Forced expiratory volume in one second (FEV1) increased with both treatments. The geometric mean plasma cortisol concentration rose after treatment with fluticasone propionate (from 293 to 309 nmol.l-1) and fell after beclomethasone dipropionate (from 256 to 224 nmol.l-1); the difference between treatments was significant. The incidence of adverse events was low in both treatment groups. In conclusion, 1 mg.day-1 fluticasone propionate was as effective as 2 mg.day-1 beclomethasone dipropionate in the control of severe asthma.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
PediatricsHome page
S. Schuh, P. T. Dick, D. Stephens, M. Hartley, S. Khaikin, L. Rodrigues, and A. L. Coates
High-Dose Inhaled Fluticasone Does Not Replace Oral Prednisolone in Children With Mild to Moderate Acute Asthma
Pediatrics, August 1, 2006; 118(2): 644 - 650.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
V. E. Murphy, P. G. Gibson, R. Smith, and V. L. Clifton
Asthma during pregnancy: mechanisms and treatment implications
Eur. Respir. J., April 1, 2005; 25(4): 731 - 750.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
V. E. Murphy, P. G. Gibson, W. B. Giles, T. Zakar, R. Smith, A. M. Bisits, C. G. Kessell, and V. L. Clifton
Maternal Asthma Is Associated with Reduced Female Fetal Growth
Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1317 - 1323.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. D. Lynd, D. P. Guh, P. D. Pare, and A. H. Anis
Patterns of Inhaled Asthma Medication Use: A 3-Year Longitudinal Analysis of Prescription Claims Data From British Columbia, Canada
Chest, December 1, 2002; 122(6): 1973 - 1981.
[Abstract] [Full Text] [PDF]


Home page
Arch Pediatr Adolesc MedHome page
F. M. de Benedictis, A. Teper, R. J. Green, A. L. Boner, L. Williams, H. Medley, and for the International Study Group
Effects of 2 Inhaled Corticosteroids on Growth: Results of a Randomized Controlled Trial
Arch Pediatr Adolesc Med, November 1, 2001; 155(11): 1248 - 1254.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
S. Holt, A. Suder, M. Weatherall, S. Cheng, P. Shirtcliffe, R. Beasley, and A. Herxheimer
Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis Commentary: Dosage needs systematic and critical review
BMJ, August 4, 2001; 323(7307): 253 - 253.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. G. Gibson, J. L. Simpson, and N. Saltos
Heterogeneity of Airway Inflammation in Persistent Asthma : Evidence of Neutrophilic Inflammation and Increased Sputum Interleukin-8
Chest, May 1, 2001; 119(5): 1329 - 1336.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
T W Harrison, A Wisniewski, J Honour, and A E Tattersfield
Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects
Thorax, March 1, 2001; 56(3): 186 - 191.
[Abstract] [Full Text]


Home page
NEJMHome page
S. Schuh, J. Reisman, M. Alshehri, A. Dupuis, M. Corey, R. Arseneault, G. Alothman, O. Tennis, and G. Canny
A Comparison of Inhaled Fluticasone and Oral Prednisone for Children with Severe Acute Asthma
N. Engl. J. Med., September 7, 2000; 343(10): 689 - 694.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
R. ZuWallack, J. Adelglass, D. P. Clifford, S. P. Duke, P. D. Wire, M. Faris, and S. M. Harding
Long-term Efficacy and Safety of Fluticasone Propionate Powder Administered Once or Twice Daily via Inhaler to Patients With Moderate Asthma
Chest, August 1, 2000; 118(2): 303 - 312.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
T C Medici, E Grebski, M Häcki, P Rüegsegger, C Maden, and J Efthimiou
Effect of one year treatment with inhaled fluticasone propionate or beclomethasone dipropionate on bone density and bone metabolism: a randomised parallel group study in adult asthmatic subjects
Thorax, May 1, 2000; 55(5): 375 - 382.
[Abstract] [Full Text]


Home page
Arch Intern MedHome page
B. J. Lipworth
Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Arch Intern Med, May 10, 1999; 159(9): 941 - 955.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. Wales, H. Makker, J. Kane, P. McDowell, and B. R. O'Driscoll
Systemic Bioavailability and Potency of High-Dose Inhaled Corticosteroids: A Comparison of Four Inhaler Devices and Three Drugs in Healthy Adult Volunteers
Chest, May 1, 1999; 115(5): 1278 - 1284.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. E. T. NOCKER, F. R. WELLER, T. A. OUT, M. J. de RIEMER, H. M. JANSEN, and J. S. van der ZEE
A Double-blind Study on the Effect of Inhaled Corticosteroids on Plasma Protein Exudation in Asthma
Am. J. Respir. Crit. Care Med., May 1, 1999; 159(5): 1499 - 1505.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
T F Fok, K Lam, M Dolovich, P C Ng, W Wong, K L Cheung, and K W So
Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome
Arch. Dis. Child. Fetal Neonatal Ed., May 1, 1999; 80(3): 203F - 208.
[Abstract] [Full Text]


Home page
ThoraxHome page
A. M Wilson and B. J Lipworth
24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids
Thorax, January 1, 1999; 54(1): 20 - 26.
[Abstract] [Full Text]


Home page
ThoraxHome page
D. Fitzgerald, P. Van Asperen, C. Mellis, M. Honner, L. Smith, and G. Ambler
Fluticasone propionate 750 µg/day versus beclomethasone dipropionate 1500 µg/day: comparison of efficacy and adrenal function in paediatric asthma
Thorax, August 1, 1998; 53(8): 656 - 661.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
P. C. Ng, T. F. Fok, G. W. K. Wong, C. W. K. Lam, C. H. Lee, M. Y. Wong, K. Lam, and K. C. Ma
Pituitary-Adrenal Suppression in Preterm, Very Low Birth Weight Infants after Inhaled Fluticasone Propionate Treatment
J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2390 - 2393.
[Abstract] [Full Text]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. J. BARNES, S. PEDERSEN, and W. W. BUSSE
Efficacy and Safety of Inhaled Corticosteroids . New Developments
Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. A. PAUWELS, J. C. YERNAULT, M. G. DEMEDTS, and P. GEUSENS
Safety and Efficacy of Fluticasone and Beclomethasone in Moderate to Severe Asthma
Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): 827 - 832.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R Donnelly, K. Williams, A. Baker, C. Badcock, R. Day, and J. Seale
Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study
Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1746 - 1751.
[Abstract] [Full Text]


Home page
Arch. Dis. Child.Home page
P. K Yiallouros, A. D Milner, E. Conway, and J. W Honour
Adrenal function and high dose inhaled corticosteroids for asthma
Arch. Dis. Child., May 1, 1997; 76(5): 405 - 410.
[Abstract] [Full Text]


Home page
BMJHome page

North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management of asthma in adults
BMJ, March 23, 1996; 312(7033): 762 - 766.
[Full Text]


Home page
DTBHome page
{blacktriangledown}Fluticasone propionate for asthma prophylaxis
DTB, April 1, 1994; 32(4): 25 - 27.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the European Respiratory Society.